- Conditions
- Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNA
- Interventions
- Tislelizumab, Fruquintinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colorectal Cancer
- Interventions
- Fruquintinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
- Interventions
- IMT-009, Fruquintinib
- Drug · Combination Product
- Lead sponsor
- Immunitas Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel
- Biological · Drug
- Lead sponsor
- AskGene Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
- Drug
- Lead sponsor
- Adagene Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
- Conditions
- Hepatic Impairment
- Interventions
- Fruquintinib
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- Fruquintinib, TheraBionic P1
- Drug · Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 9
- States / cities
- Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 6 more
- Conditions
- Drug Drug Interaction
- Interventions
- Fruquintinib, Itraconazole, Rifampin
- Drug
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
- Interventions
- Fruquintinib, Tislelizumab
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- New Haven, Connecticut • Miami Beach, Florida • Orlando, Florida + 10 more
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
- Interventions
- fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 14
- States / cities
- Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more
- Conditions
- Advanced Malignancies
- Interventions
- Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Renal Impairment
- Interventions
- Fruquintinib
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Colorectal Cancer
- Interventions
- DSP107 + Atezolizumab, Fruquintinib
- Drug
- Lead sponsor
- Kahr Bio Australia Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Highlands Ranch, Colorado • Florida City, Florida + 3 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Fruquintinib, Dabigatran Etexilate, Rosuvastatin
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Metastatic Colorectal Cancer, Metastatic Colon Cancer
- Interventions
- Fruquintinib, Placebo
- Drug
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 39 more
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Fruquintinib Combined With Chemotherapy
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
- Interventions
- Fruquintinib (HMPL-013)
- Drug
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more
- Conditions
- Drug Interaction, Food-drug Interaction
- Interventions
- fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
- Drug
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Colon Cancer, Metastatic Colon Cancer
- Interventions
- ST316, FOLFIRI regimen & bevacizumab, Fruquintinib, Lonsurf & bevacizumab
- Drug
- Lead sponsor
- Sapience Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more